All News

Sign

Emapalumab for the treatment of macrophage activation syndrome

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly occurring in people with systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE).

Read Article
heel enthesitis spur calcaneal

Predicting RA, and Treatment of Subclinical Arthritis

d Meral K. El Ramahi, MD, FACP, FACR

Identifying patients that will develop RA in situations of seropositivity without overt clinical arthritis or identifying patients with undifferentiated oligo/polyarthritis that will develop RA remains a challenge in the field of rheumatology. 

Read Article
unhappy%20patient.jpg

Psoriatic Arthritis: "What Matters" to Patients, Physicians

d Swetha Ann Alexander, MD

A study presented today by Mease et al. addresses the vital gap between what patients and physicians consider disabling because of PsA, and emphasizes “what matters” in a daily clinical encounter while dealing with PsA.

Read Article
Does Obesity Play a Role in Biologic Response? Dr. Eric Dein ( @ejdein1) discusses abstract #0588 presented at the #ACR21 annual meeting. https://t.co/yJNOFv3KOC https://t.co/KvBrFlXLfW

Links:

Dr. John Cush RheumNow ( View Tweet)
Radiographic Progression in SpA: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0907 and #0897 presented at the #ACR21 annual meeting. https://t.co/9hStWrfPOW https://t.co/XkgDjXE7Aq

Links:

Dr. John Cush RheumNow ( View Tweet)
Can "Ultra-low" dose Rituximab work for RA? At day 3 of #ACR21, the REDO trial presented data in abs1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Dr. Eric Dein ( @ejdein1) shares highlights. https://t.co/jaTjBPRKVe https://t.co/7Q9nxlUt7R

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis: What's with Brepocitinib? Dr. Eric Ruderman ( @JointMD ) discusses abstract #0488 presented at the #ACR21 annual meeting. https://t.co/mq0IMwyMSk https://t.co/oJAJS0DpQz

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus Day 2 Highlights: Drs Dao , Mehta, Yusof, Pope, Reyes and Castillo review lupus-related information and data presented during day 2 of the #ACR21 annual meeting. https://t.co/QX6Ay77FKo @KDAO2011 @bella_mehta @Yuz6Yusof @Janetbirdope @RHEUMarampa @_Castillo_Pedro https://t.co/ldAHqXsi0G

Links:

Dr. John Cush RheumNow ( View Tweet)
RA: Cardiovascular Risk Stratification and Potential Predictors of Risk Dr. El Ramahi ( @MeralElRamahiMD ) shares important takeaways from abstracts presented at #ACR21. https://t.co/69E7aA0Wag https://t.co/6nR5TLeyga

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Roundtable Rehash of #ACR21 New therapies, delay in diagnosis, artificial intelligence in reading radiographs and MRIs, and more. Panelists includes Dr. Alexis Ogdie-Beatty, Dr. Jose Scher, Dr. Jack Cush and Dr. Christopher Ritchlin. https://t.co/K0pbddzLAF https://t.co/fS6wBNWOdJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Day 4 Report from #ACR21 My favorite three presentations from day 4 at ACR 2021 included the following: -Breakthrough Infections in Rheumatic Disease Patients -Secukinumab in Giant Cell Arteritis -STOP-Gout – Febuxostat is Noninferior to Allopurinol https://t.co/zJRS5AHjc1 https://t.co/FuwCFCK14r

Links:

Dr. John Cush RheumNow ( View Tweet)
Cognitive Impairment in Patients with Rheumatoid Arthritis Dr. Akhil Sood ( @AkhilSoodMD) discusses abstracts presented at #ACR21. https://t.co/zz8auqZjIW https://t.co/RSHjyonBrj

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors to Flare in SpA: Dr. Antoni Chan ( @synovialjoints ) discusses abstracts #0929 and #0916 presented at the #ACR21 annual meeting. https://t.co/C0NLSTzlW9 https://t.co/3BiW2L6BJu

Links:

Dr. John Cush RheumNow ( View Tweet)
Can we Use Frax Score in RA Patients? Dr. Eric Dein ( @ejdein1) reviews abstract #0563 presented at the #ACR21 annual meeting. https://t.co/UcvTWhlcvW https://t.co/8AdHa2enlz

Links:

Dr. John Cush RheumNow ( View Tweet)
An Exclusive Interview with Dr. Al Kim (#Wowkim): Dr. Kathryn Dao ( @KDAO2011 ) interviews Dr. Alfred Kim (aka #Wowkim) about the exciting work he's presenting at the #ACR21 annual meeting. https://t.co/34EZIz2OFG https://t.co/mhaUcIhTKu

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR21 Best Abstracts - Day 4 On the last day of #ACR21 Annual Meeting, the RheumNow faculty selected their favorite reports. Follow the link below for our selections! https://t.co/O6IXf5iB3d https://t.co/G1yUzqwcuk

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors of Remission and Low Disease Activity in SLE Dr. Sheila Reyes ( @RHEUMarampa) shares results of abstracts discussed at #ACR21. https://t.co/FayzgyGiP8 https://t.co/QvKbKnznmS

Links:

Dr. John Cush RheumNow ( View Tweet)
Serum Biomarkers Distinguish Radiographic Progression in PsA: Dr. Robert Chao ( @doctorRBC ) discusses abstract #0449 presented at the #ACR21 annual meeting. https://t.co/Q9JQyx7K1A
Dr. John Cush RheumNow ( View Tweet)
Emapalumab for the treatment of macrophage activation syndrome Dr. Yuz Yusof ( @Yuz6Yusof) summarizes abstracts presented at #ACR21. https://t.co/TXdbwA64wg https://t.co/VLiLIsEkxS

Links:

Dr. John Cush RheumNow ( View Tweet)
Predictors of mortality in RA lung disease? Dr. Meral El Ramahi ( @MeralElRamahiMD) discusses abstract #0290 presented at the #ACR21 annual meeting. https://t.co/swo0eexWHl https://t.co/dVpeTQIwTb

Links:

Dr. John Cush RheumNow ( View Tweet)
×